Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General Hospital
Not Applicable
Completed
- Conditions
- Multiple MyelomaBlood - Haematological diseases
- Registration Number
- ACTRN12612000024842
- Lead Sponsor
- Clifford Craig Medical Trust Fund
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Patients with multiple myeloma who have a light chain disease and renal impairment
Exclusion Criteria
patients who have low light chain disease that not cause renal impairment
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Myeloma active parameters: amount of light chain disease, bone marrow disease, lytic lesions, hypercalcaemia and renal function.<br><br>Assessed by serum free light chain, calcium level, bone marrow biopsy, radiological imaging and kidney function test[These will be assessed continously until the end of the study.]
- Secondary Outcome Measures
Name Time Method Disease outcome.<br>Assessed by overall disease remission status and survival rate[These will be assessed continously until the end of the study.]